Astrana Health, Inc. (NASDAQ:ASTH – Get Free Report) has earned a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $45.00.
Several research firms have commented on ASTH. Weiss Ratings raised shares of Astrana Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 1st. Truist Financial increased their price objective on shares of Astrana Health from $38.00 to $47.00 and gave the company a “buy” rating in a report on Thursday, May 14th. TD Cowen increased their price target on shares of Astrana Health from $35.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Robert W. Baird set a $45.00 price target on shares of Astrana Health in a report on Friday, May 8th. Finally, Needham & Company LLC increased their price target on shares of Astrana Health from $30.00 to $41.00 and gave the company a “buy” rating in a report on Friday, May 8th.
Get Our Latest Stock Report on ASTH
Institutional Inflows and Outflows
Astrana Health Stock Up 2.9%
ASTH opened at $39.85 on Friday. The firm has a 50-day simple moving average of $34.58 and a two-hundred day simple moving average of $27.44. Astrana Health has a 52 week low of $18.08 and a 52 week high of $40.13. The company has a market capitalization of $2.22 billion, a PE ratio of 65.33 and a beta of 1.00. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 1.20.
Astrana Health (NASDAQ:ASTH – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.74 EPS for the quarter, beating the consensus estimate of $0.29 by $0.45. Astrana Health had a net margin of 0.86% and a return on equity of 9.22%. The business had revenue of $965.10 million during the quarter, compared to the consensus estimate of $949.21 million. During the same quarter in the prior year, the firm earned $0.42 EPS. The business’s revenue was up 55.6% on a year-over-year basis. Analysts forecast that Astrana Health will post 1.25 earnings per share for the current fiscal year.
Astrana Health Company Profile
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.
Recommended Stories
- Five stocks we like better than Astrana Health
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.
